THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW
Press release Regulated information Nov. 4, 2014 – 6:00 PM
MDxHealth Launches Equity Placement
IRVINE, CA, and HERSTAL, BELGIUM – November 4, 2014 – MDxHealth SA (Euronext Brussels : MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, announced today that it has launched an offering of up to 3,425,000 new shares by means of a private placement with a group of institutional, qualified and professional investors in and outside Belgium.
Petercam NV/SA acts as Sole Lead Manager and Book Runner for the private placement, which shall be structured as an accelerated bookbuilding. The bookbuilding procedure will commence immediately and is expected to close on November 5, 2014, subject to acceleration or extension of the timetable.
The net proceeds of the private placement will be used to support and scale-up MDxHealth’s U.S.-based managed care and related healthcare reimbursement efforts, together with its sales and marketing efforts. In addition, depending on the amount raised, the net proceeds would be used to accelerate product development and for general corporate purposes.
MDxHealth will request the admission to trading of the newly issued shares on Euronext Brussels. The trading in MDxHealth shares on Euronext Brussels will be suspended throughout the bookbuilding period. Trading in the stock is expected to resume following the publication of the results of the placement.
The company will announce the results of the placement as soon as possible after closing of the bookbuilding in a subsequent press release.
About MDxHealth®
MDxHealth is a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment. The company's tests are based on proprietary gene methylation (epigenetics) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit mdxhealth.com and follow us on Twitter at twitter.com/mdxhealth